Having walked Generics Bulletin through Formycon’s key portfolio and pipeline assets in the first part of his exclusive interview (see sidebar), the second part of the discussion saw CEO Stefan Glombitza taking a step back to discuss the German biosimilars developer’s broader portfolio selection strategy in more detail.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
Formycon CEO Talks Candidate Selection Strategy And Recent Biosimilar Regulatory Changes
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
